Artiva ends AlloNK and cuts about 94% of staff after a risk-benefit review covering durability and two separately assessed deaths. Ferring agrees to acquire Gameto for up to $1.3825 billion subject to milestones, before Fertilo's pivotal fertility trial reports. Pfizer's ELREXFIO (elranatamab) meets a Phase 3 myeloma goal with higher rates of severe infections; AstraZeneca and Daiichi Sankyo gain EU approval for Enhertu (trastuzumab deruxtecan) in postoperative HER2-positive early breast cancer; Novartis discontinues remibrutinib in generalized myasthenia gravis for futility. Also: Teva closes its BioXcel asset deal for IGALMI (dexmedetomidine) and the pending at-home BXCL501 program; Vanda's NEREUS (tradipitant) reduces vomiting in a single-dose semaglutide challenge; and Kiniksa raises its ARCALYST (rilonacept) sales forecast.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →